MedTrace Logo

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

NCT01805908 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-06-06

No results posted yet for this study

Summary

The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body Single Photon Emission Computed Tomography (SPECT) imaging to predict who will respond to treatment with Trastuzumab.

Conditions

Interventions

OTHER

111In-Pertuzumab + SPECT-CT

111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.

Sponsors & Collaborators

  • Ontario Clinical Oncology Group (OCOG)

    lead OTHER

Principal Investigators

  • Mark Levine · Ontario Clinical Oncology Group, McMaster University

  • Raymond Reilly · University of Toronto

  • Kathleen Pritchard · Ontario Clinical Oncology Group (OCOG)

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805908 on ClinicalTrials.gov